BCAT1 and myeloproliferative neoplasm: BCAT1 inhibition could provide a therapeutic strategy for MPN patients who have elevated BCAT1 (e.g., patients with EZH2, and possibly ASXL1 and SRSF2 mutations) to shift malignant myeloproliferative hematopoiesis back to normal hematopoiesis.